Frequently Asked Questions
The South Asia Molecular Point of Care Testing (using NAAT) Market will grow at a CAGR of 10.8% by 2028.
The significant factors flourishing the growth of the South Asia Molecular Point of Care Testing (using NAAT) Market are RISe in PREFERENCE FOR HOMECARE TESTING, and INCREase in PREVALENCE OF CHRONIC DISEASES.
The major players operating in the South Asia Molecular Point of Care Testing (using NAAT) Market are SD Biosensor, Inc., Abbott, F.Hoffmann-La Roche Ltd., Danaher, Thermo Fisher Scientific Inc, binx Health, Inc., Lucira, Meridian Bioscience, Quantumdx Group Ltd., BD, Biomérieux Sa, Qiagen, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories, Inc., Sekisui Diagnostic, Randox Laboratories Ltd., GenMark Diagnostics, Seegene Inc. Grifols S.A., Wondfo, Oxford Nanopore Diagnostic, PerkinElmer Inc., and Co-Diagnostic.
The major countries covered in the South Asia Molecular Point of Care Testing (using NAAT) Market are India, Pakistan, Bangladesh, and the rest of South Asia.
